Laboratorios Farmaceuticos Rovi, S.A. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was EUR 201.63 million compared to EUR 205.58 million a year ago. Net income was EUR 47.46 million compared to EUR 53.05 million a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
90.15 EUR | +1.46% | +5.13% | +49.75% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+49.75% | 4.99B | |
+37.98% | 723B | |
+34.08% | 595B | |
-2.87% | 369B | |
+20.30% | 332B | |
+2.65% | 282B | |
+16.96% | 244B | |
+9.51% | 208B | |
-4.70% | 205B | |
+0.80% | 168B |
- Stock Market
- Equities
- ROVI Stock
- News Laboratorios Farmaceuticos Rovi, S.A.
- Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023